| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Estrogen Receptor/ERR
(E)-4-Hydroxytamoxifen targets the estrogen receptors (ERalpha and ERbeta). As a SERM, it functions as an antagonist in breast tissue while maintaining partial agonist effects in other tissues such as bone and endometrium. The compound binds with high affinity to estrogen receptors, blocking the effects of estrogen in breast tissue, and is being studied for its potential use in hormone-related conditions. |
|---|---|
| ln Vitro |
Afimoxifene is a tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.
(E)-4-Hydroxytamoxifen demonstrates potent in vitro anti-estrogenic activity. It binds specifically to the estrogen receptor and inhibits its ability to bind to DNA. The compound has been shown to have anti-cancer effects in breast cancer cells and decreases Ca2+ amplitude in cardiac myocytes, slowing relaxation and decreasing contractility. It acts as an agonist or antagonist in various tissues. |
| ln Vivo |
In vivo, (E)-4-Hydroxytamoxifen is the active metabolite responsible for the therapeutic effects of tamoxifen. It exerts its anti-estrogenic effects by binding to estrogen receptors and modulating gene expression. The compound has demonstrated both in vivo and in vitro properties as a non-steroidal antiestrogen. It is used in research models to study hormone-dependent cancers and the tissue-specific effects of SERMs.
|
| Enzyme Assay |
In vitro receptor binding assays for (E)-4-Hydroxytamoxifen typically employ radioligand binding using estrogen receptor (ER) preparations from breast cancer cell lines such as MCF-7. Membranes are incubated with varying concentrations of the compound and a fixed concentration of [3H]-estradiol. Non-specific binding is determined using an excess of unlabeled estradiol. Binding affinity (IC50 or Ki) is calculated from competition curves.
|
| Cell Assay |
In vitro cellular assays for (E)-4-Hydroxytamoxifen involve treating estrogen receptor-positive breast cancer cell lines (e.g., MCF-7, T47D) with varying concentrations of the compound (typically 0.001-10 microM range) for 24-72 hours. Readouts include cell viability/proliferation assays (MTT, CellTiter-Glo), assessment of estrogen-responsive gene expression by qPCR, and estrogen receptor-mediated transcriptional activity using reporter gene assays.
|
| Animal Protocol |
In vivo animal studies for (E)-4-Hydroxytamoxifen typically employ ovariectomized rodent models or xenograft mouse models bearing estrogen receptor-positive tumors. Animals are administered the compound via subcutaneous injection, intraperitoneal injection, or oral gavage at various doses. Endpoints include tumor growth inhibition, uterine weight (as a measure of estrogenic activity), bone density, and assessment of estrogen-responsive biomarker modulation.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
It is absorbed after local application. Pharmacokinetic properties of (E)-4-Hydroxytamoxifen are characteristic of its role as the active metabolite of tamoxifen. Following tamoxifen administration, 4-hydroxytamoxifen is formed via cytochrome P450-mediated metabolism (primarily CYP2D6 and CYP3A4). The compound exhibits high protein binding and tissue distribution. PK parameters including half-life, Cmax, and AUC are determined via LC-MS/MS analysis. |
| Toxicity/Toxicokinetics |
(E)-4-Hydroxytamoxifen is a research-grade compound used for laboratory purposes only. As with all SERMs, potential toxicities may include thromboembolic events and endometrial effects associated with its partial agonist activity. Standard safety precautions should be observed during handling including appropriate PPE and work in a fume hood. The compound is not intended for human therapeutic use.
|
| Additional Infomation |
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol is a stilbene compound. Afimoxifene (4-hydroxytamoxifen, trade name TamoGel) is a novel estrogen inhibitor currently under investigation for the treatment of various estrogen-dependent disorders, including cyclical breast pain and gynecomastia. TamoGel is formulated using enhanced hydroalcoholic gel (EHG) technology. This technology enables transdermal drug delivery, allowing for drug delivery that cannot be taken orally. It was developed by Ascent Therapeutics. Afimoxifene is a metabolite of tamoxifen and has both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for estrogen receptors than tamoxifen and acts as an antagonist in breast cancer cells. Indications: For the treatment of cyclical breast pain, fibrocystic breast disease, breast disease, gynecomastia, and keloids.
Mechanism of Action Afimoxifene binds to the estrogen receptor (ER), inducing a conformational change in the receptor. This leads to the blockade or alteration of estrogen-dependent gene expression. Afimoxifene binds to the estrogen receptor (ER), inducing a conformational change in the receptor. This results in the blockade or alteration of estrogen-dependent gene expression. (E)-4-Hydroxytamoxifen (CAS# 174592-47-3), also known as Afimoxifene, is the active metabolite of tamoxifen, an anticancer drug and SERM. It is the less active isomer of 4-hydroxytamoxifen. The compound is not approved as a standalone therapeutic agent but is widely used as a research tool to study estrogen receptor biology and hormone-dependent cancers. It is typically stored at -20degC. Not for human therapeutic use. |
| Molecular Formula |
C26H29NO2
|
|---|---|
| Molecular Weight |
387.51396
|
| Exact Mass |
387.22
|
| Elemental Analysis |
C, 80.59; H, 7.54; N, 3.61; O, 8.26
|
| CAS # |
174592-47-3
|
| Related CAS # |
4-Hydroxytamoxifen;68047-06-3;(E/Z)-4-Hydroxytamoxifen;68392-35-8; 174592-47-3 (E-isomer)
|
| PubChem CID |
5352135
|
| Appearance |
White to off-white solid powder
|
| Density |
1.092g/cm3
|
| Boiling Point |
514.4ºC at 760 mmHg
|
| Flash Point |
264.9ºC
|
| Vapour Pressure |
3.35E-11mmHg at 25°C
|
| Index of Refraction |
1.596
|
| LogP |
5.701
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
29
|
| Complexity |
493
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=C(C=C1)/C(C2=CC=C(C=C2)OCCN(C)C)=C(CC)\C3=CC=CC=C3
|
| InChi Key |
TXUZVZSFRXZGTL-OCEACIFDSA-N
|
| InChi Code |
InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25+
|
| Chemical Name |
4-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
|
| Synonyms |
Afimoxifene; Afimoxifene, E-isomer; 68392-35-8; E-4-Hydroxytamoxifen; AKE3PH0IML; CHEMBL279301; (E)-4-Hydroxytamoxifen; cis-4-Hydroxytamoxifen; 4-((1E)-1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~32.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5806 mL | 12.9029 mL | 25.8058 mL | |
| 5 mM | 0.5161 mL | 2.5806 mL | 5.1612 mL | |
| 10 mM | 0.2581 mL | 1.2903 mL | 2.5806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
